Please login to the form below

Not currently logged in
Email:
Password:

Michael Cola resigns as president of Shire Specialty Pharmaceuticals

Leaves to "explore new career opportunities and challenges”

Michael Cola - ShireShire's Michael Cola is to resign as president of the company's specialty pharmaceuticals business.

“With the company in a position of tremendous strength it is time for me to explore new career opportunities and challenges,” he said. “It has been an honour to work with my colleagues at Shire.”

Cola had been with Shire for seven years, joining as executive VP and general manager for the company's global therapeutic business units.

He assumed the role of president of the specialty pharmaceuticals business in 2006.

His role will be taken over by the company's CEO Angus Russell while the search for a new president is carried out.

Russell said: “As president of the SP business, Mike was instrumental in helping Shire transform itself from a company dominated by a single product in one market to a leading global biopharmaceutical company with a diversified product portfolio.”

Prior to joining Shire, Cola held several executive positions at pharma companies, including Merck,  AstraZeneca and Safeguard Scientifics.

3rd April 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics